GlassScriptPhysician profile
Ronak R Patel
NPI 1821247354
$1,784.63
in general payments reported to CMS, 2019-2025
21 companies · $476 in 2025
The $476 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $36.10 · 2021: $206 · 2022: $65.44 · 2023: $323 · 2024: $241 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.06 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $378.38 | 2021-2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Novo Nordisk INC | $310.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $239.94 | 2019-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $221.15 | 2023-2025 | Minimed 780g |
| Zyla Life Sciences, INC. | $174.92 | 2019 | |
| Mannkind Corporation | $63.37 | 2019-2023 | Afrezza |
| Medtronic Minimed, INC. | $62.19 | 2019 | |
| Lilly USA, LLC | $56.18 | 2022-2023 | Mounjaro |
| Tandem Diabetes Care, INC. | $39.95 | 2019-2020 | |
| Intuity Medical INC | $30.14 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Abbott Laboratories | $29.58 | 2023-2024 | Freestyle Libre |
| Celgene Corporation | $24.44 | 2022 | |
| Fresenius Kabi USA, LLC | $22.67 | 2025 | Tyenne |
| Sequel Med Tech, LLC | $19.91 | 2025 | Twiist |
| Cequr Corporation | $19.88 | 2023 | Cequr Simplicity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $19.50 | 2024 | Senza |
| Astrazeneca Pharmaceuticals LP | $14.99 | 2019 | |
| Amgen INC. | $14.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.45 | 2024 | |
| Janssen Pharmaceuticals, INC | $14.14 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.92 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.